Answers are grounded in this paper and cite their sources.
Preclinical study demonstrates that a self-assembling protein nanovaccine protects against Echinococcus multilocularis infection, highlighting a potent platform for parasitic disease immunization.
Alveolar echinococcosis (AE) i s a life-threatening zoonotic disease caused by the larval stage of Echinococcus multilocularis ( E. multilocularis ). It is characterized by the tumor-like invasive growth pattern and limited treatment options. Although immunoprophylaxis represents a promising strategy, it is difficult to achieve sufficient immune activation without disrupting Th1/Th2 immune homeostasis. Here we report a cage-assembled antigenic particle vaccine (CAP-V) that leverages a self-assembling protein nanocage to elicit protective antiparasitic immunity. CAP-V is constructed using an engineered circularly permuted E2 (CPE2) scaffold to display the full-length E. multilocularis 14-3-3 antigen through either genetic fusion or post-assembly SpyCatcher–SpyTag conjugation. Both vaccine sequence formulations assemble into homogeneous nanoparticles and can be efficiently produced in Escherichia coli . Mechanistically, CAP-V induced BMDC maturation-associated responses and coordinated cellular and humoral immunity. In vivo immunization elicited concurrent Th1- and Th2-associated responses, with a comparatively stronger IFN-γ/IgG2c-associated component. Importantly, this coordinated immune profile is associated with significant protection against E. multilocularis challenge, reflected by reduced parasite burden and ameliorated tissue pathology. Together, these findings demonstrate Em14-3-3 CAP-Vs as a modular and mechanistically informed protein nanovaccine platform and highlight its potential for immunoprophylaxis against AE and other chronic helminthic diseases.
No takes yet. Share an insight, caveat, or question.
Zang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: